Several Circulating Biomarkers for PCOS Diagnosis

Area of Science:

• Endocrinology
• Reproductive Medicine
• Biomarker Discovery

Background:

• Polycystic ovary syndrome (PCOS) is a complex endocrine disorder.
• Irisin, Betatrophin, and Zinc-α2-glycoprotein (ZAG) are implicated in insulin resistance (IR) and PCOS.
• Accurate screening tools for PCOS are crucial for early diagnosis and management.

Purpose of the Study:

• To evaluate the diagnostic accuracy of individual and combined serum levels of Irisin, Betatrophin, and ZAG for screening PCOS.
• To investigate the association of these biomarkers with insulin resistance in PCOS patients.

Main Methods:

• Enzyme-linked immunosorbent assay (ELISA) was used to measure serum concentrations of Irisin, Betatrophin, and ZAG in 186 participants.
• Logistic regression analysis assessed the association between biomarkers and PCOS.
• Receiver operating curve (ROC) analysis determined the diagnostic value of these biomarkers.

Main Results:

• PCOS women exhibited significantly higher Irisin and Betatrophin levels and lower ZAG levels compared to controls.
• Lower ZAG and higher Irisin/Betatrophin levels were observed in PCOS women with IR.
• Individual AUCs were 0.77 (Irisin), 0.83 (ZAG), and 0.85 (Betatrophin).
• Combined analysis yielded an AUC of 0.93 with 82.1% sensitivity and 92.3% specificity for PCOS detection.

Conclusions:

• The combination of Irisin, ZAG, and Betatrophin significantly enhances diagnostic accuracy for PCOS compared to single biomarkers.
• This multi-biomarker panel shows potential as an effective screening tool for PCOS.
• Further research may validate this panel for clinical application in PCOS diagnosis.